MedTrace Logo

Steroid Treatment for Elimination of Rebound Obstruction From Intranasal Decongestants

NCT07168148 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2026-03-23

No results posted yet for this study

Summary

This prospective, virtually administered trial conducted throughout the United States aims to evaluate a standardized protocol including the serial dilution of topical decongestants with concurrent topical steroids (triamcinolone), for elimination of dependence on topical decongestants.

Conditions

  • Nasal Obstruction
  • Chronic Rhinitis

Interventions

DRUG

Oxymetazoline + Triamcinolone

Participants will be stratified according to this usage and placed into a titration schedule. * Titration 1: 0.05% 5x/day, * Titration 2: 0.05% 4x/day, * Titration 3: 0.05 3x/day, * Titration 4: 0.05% 2x/day. Participants with twice daily use, will then be placed in a titration schedule for oxymetazoline concentration which will stop when the oxymetazoline concentration is set to zero. * Titration 5: 0.0375% Afrin/Nasacort 2x/day, * Titration 6: 0.025% Afrin/Nasacort 2x/day, * Titration 7: 0.0125% Afrin/Nasacort 2x/day, * Titration 8: 0.0% Afrin/Nasacort 2x/day.

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Nyssa Farrell, MD · Washington University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-10
Primary Completion
2026-03-19
Completion
2026-03-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07168148 on ClinicalTrials.gov